212 related articles for article (PubMed ID: 35094126)
1. Effects of suspension of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration in clinical setting.
Matsubara H; Matsui Y; Miyata R; Ichio A; Chujo S; Enomoto H; Sugimoto M; Kondo M
Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1867-1876. PubMed ID: 35094126
[TBL] [Abstract][Full Text] [Related]
2. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
3. [Neovascular recurrences in 42 treatment-naive eyes with neovascular age-related macular degeneration (AMD) followed for over 2 years].
Bodénès F; Massé H; Lebreton O; Weber M
J Fr Ophtalmol; 2021 May; 44(5):626-631. PubMed ID: 33840491
[TBL] [Abstract][Full Text] [Related]
4. Recurrent Neovascular Age-Related Macular Degeneration after Discontinuation of Vascular Endothelial Growth Factor Inhibitors Managed in a Treat-and-Extend Regimen.
Aslanis S; Amrén U; Lindberg C; Epstein D
Ophthalmol Retina; 2022 Jan; 6(1):15-20. PubMed ID: 33775926
[TBL] [Abstract][Full Text] [Related]
5. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
Inan S; Polat O; Karadas M; Inan UU
Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
[No Abstract] [Full Text] [Related]
6. Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment: A Retrospective Cohort Study.
Kuroda Y; Yamashiro K; Miyake M; Yoshikawa M; Nakanishi H; Oishi A; Tamura H; Ooto S; Tsujikawa A; Yoshimura N
Ophthalmology; 2015 Nov; 122(11):2303-10. PubMed ID: 26271842
[TBL] [Abstract][Full Text] [Related]
7. Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19.
Keenan TD; Vitale S; Agrón E; Domalpally A; Antoszyk AN; Elman MJ; Clemons TE; Chew EY;
Ophthalmol Retina; 2020 Jan; 4(1):3-12. PubMed ID: 31395505
[TBL] [Abstract][Full Text] [Related]
8. Ten-year survival trends of neovascular age-related macular degeneration at first presentation.
Arpa C; Khalid H; Chandra S; Wagner S; Fasler K; Faes L; Pooprasert P; Chopra R; Moraes G; Balaskas K; Keane PA; Sivaprasad S; Fu DJ
Br J Ophthalmol; 2021 Dec; 105(12):1688-1695. PubMed ID: 33011683
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Intentionally Suspending Treatment in Eyes With Advanced Neovascular Age-Related Macular Degeneration.
Awh KC; Mahmoudzadeh R; Salabati M; Mansour HA; Bechay J; Magagna J; Regillo CD; Ho AC; Garg SJ; Hsu J
Am J Ophthalmol; 2023 Dec; 256():20-26. PubMed ID: 37517527
[TBL] [Abstract][Full Text] [Related]
10. Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration.
Hörster R; Ristau T; Sadda SR; Liakopoulos S
Graefes Arch Clin Exp Ophthalmol; 2011 May; 249(5):645-52. PubMed ID: 21170547
[TBL] [Abstract][Full Text] [Related]
11. Anatomical effects of intravitreal anti-vascular endothelial growth factor injections on inner layers of the lesion-free retina.
Demir N; Sevincli S; Kayhan B; Sonmez M
Cutan Ocul Toxicol; 2021 Jun; 40(2):135-139. PubMed ID: 33944638
[TBL] [Abstract][Full Text] [Related]
12. Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents.
Evans RN; Reeves BC; Maguire MG; Martin DF; Muldrew A; Peto T; Rogers C; Chakravarthy U
JAMA Ophthalmol; 2020 Oct; 138(10):1043-1051. PubMed ID: 32816002
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
[TBL] [Abstract][Full Text] [Related]
14. Long-term Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: The LATAR Study: Report 1: Ten-Year, Real-World Outcomes.
Spooner K; Fraser-Bell S; Hong T; Phan L; Wong JG; Chang A
Ophthalmol Retina; 2021 Jun; 5(6):511-518. PubMed ID: 33007523
[TBL] [Abstract][Full Text] [Related]
15. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
Steinle NC; Du W; Gibson A; Saroj N
Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
[TBL] [Abstract][Full Text] [Related]
16. Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials.
Yamashiro K; Oishi A; Hata M; Takahashi A; Tsujikawa A
Jpn J Ophthalmol; 2021 Nov; 65(6):741-760. PubMed ID: 34491474
[TBL] [Abstract][Full Text] [Related]
17. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
[TBL] [Abstract][Full Text] [Related]
18. Mental Status and Feasibility of an Intravitreal Ranibizumab Treat-and-Extend Regimen in Patients with Neovascular Age-Related Macular Degeneration.
Kato A; Yasukawa T; Sugita I; Yoshida M; Nozaki M; Hirano Y; Kondo J; Abe T; Sugita K; Okita T; Morita H; Takase N; Ogura Y
Adv Ther; 2022 Mar; 39(3):1403-1416. PubMed ID: 35112307
[TBL] [Abstract][Full Text] [Related]
19. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
20. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
